

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 27th May, 2019

To,
The Bombay Stock Exchange Limited,
Corporate Services Department,
Phiroze Jeejeebhoy Tower, Dalal Street,
Mumbai-400 001

**SUBJECT : SUBMISSION OF FORM 'A' OF REGULATION 33 (3) OF THE SEBI
(LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS)
REGULATIONS, 2015 ALONG WITH THE FINANCIAL RESULTS OF THE
COMPANY FOR YEAR ENDED 31.03.2019**

SCRIPT ID : 506365

Dear Sir,


We wish to submit Form 'A', Declaration along with the Audited Financial Results of the Company pursuant to the Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, in order to comply with the provisions of Listing Agreement.

Kindly find the requisite document.

Thanking You,

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED


ASHOK SOMANI
DIRECTOR
(DIN NO. - 03063364)



Encl.: as above

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001






• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC0035556 • PAN NO.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

DECLARATION

Declaration regarding Un-Modified Audit Report in respect Standalone Financial Statements for the Financial Year 2018-2019 under SEBI (Listing Obligations and Disclosure Requirements)(Amendment) Regulations, 2016.

We hereby declare that we have submitted the Audit Reports in respect of Standalone Financial Statements for the year 2018-2019, along with the Financial Results on 27th May, 2019. We hereby confirm that auditors have expressed an unmodified opinion in their Audit Reports on Standalone Financial Statements.

1.	Name of the Company:	CHEMO PHARMA LABORATORIES LIMITED
2.	Annual Financial Statements for the year ended	31 st March, 2019
3.	Type of Audit observation	Un-Qualified
4.	Frequency of observation	-
5.	To be signed by-	
	• CEO – SHREENIWAS SOMANI	
	• CFO – ASHOK SOMANI	
	• Auditor of the Company – VMD & Co.	 For VMD & Co.  Partner CA. Amit S. Ganpule Mem. No. 114222
	• Audit Committee Chairman – BALKISHAN LOHIA	

CHEMO PHARMA LABORATORIES LIMITED





Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

FORM A as per Regulation 33 (3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

1.	Name of the Company:	CHEMO PHARMA LABORATORIES LIMITED
2.	Annual Financial Statements for the year ended	31 st March, 2019
3.	Type of Audit observation	Un-Qualified
4.	Frequency of observation	-
5.	To be signed by-	
	• CEO – SHREENIWAS SOMANI	
	• CFO – ASHOK SOMANI	
	• Auditor of the Company – VMD & Co.	
	• Audit Committee Chairman – BALKISHAN LOHIA	



Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of **CHEMO PHARMA LABORATORIES LIMITED**


We have audited the quarterly financial results of Chemo Pharma Laboratories Limited for the quarter ended March 31, 2019 and the year to date results for the period April 1, 2018 to March 31, 2019 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2019 as well as the year to date results for the period from April 1, 2018 to March 31, 2019.

For VMD & Co.
Chartered Accountants
FRN: 125002W


CA Amit Ganpule
Partner
MRN: 114222



Place : Mumbai
Date: May 27, 2019
No. : A/02/0519

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDLONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2019

Sr. No.	Particulars	(Rupees in Thousand)				
		Quarter Ended			Year Ended	
		31st March 2019	31st Dec., 2018	31st March 2018	31st March 2018	31st March 2019
		Unaudited	Unaudited	Unaudited	Audited	Audited
I	Revenue from Operations			-	-	-
II	Other Income	4,266	1,420	4,112	11,055	8,225
III	Total Revenue (I + II)	4,266	1,420	4,112	11,055	8,225
IV	Expenses					
	(1) Cost Materials consumed	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-
	(4) Finance Costs	-	-	-	-	-
	(5) Employee Benefits Expenses	526	624	397	1,564	2,218
	(6) Depreciation and Amortisation Expenses	-	-	35	35	47
	(7) Administrative and Other Expenses	854	284	66	417	3,414
	i) Professional Charges	-	125	256	991	-
	ii) Share Registry Expenses	-	269	23	100	-
	iii) Annual Listing Fees	-	-	-	315	-
	iv) Postal Charges	-	-	-	-	-
	Total Expenses	1,380	1,302	777	3,422	5,679
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	2,886	118	3,335	7,633	2,546
VI	Exceptional Items	-	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	2,886	118	3,335	7,633	2,546
VIII	Extra Ordinary Items	-	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	2,886	118	3,335	7,633	2,546
X	Tax Expenses					
	(1) Current Tax	460	-	1,450	1,450	460
	(2) Tax Adjusted Previous Year	-	-	-	5,177	23
	(3) Deferred Tax	-	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	2,426	118	1,885	1,006	2,063
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	2,426	118	1,885	1,006	2,063
XVI	Other Comprehensive Income					
	A (i) Itmes that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss					
	B (i) Itmes that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Incoe for the period	2,426	118	1,885	1,006	2,063
XVIII	Earnings per Share :					
	(1) Basic	1.62	0.08	1.26	0.67	1.38
	(2) Diluted					

Notes :

- 1 This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.



- 2 The above Standlone Audited Financial Results for the Quarter and Year Ended 31.03.2019 have been reviewed by the Audit Committee in their Meeting held on 27.05.2019 and approved by the Board of Directors of its Meeting held on 27.05.2019. The Audit Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- 3 The Company is not having any Subsidiary Company.
- 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

Place : Mumbai
Date : 27th May, 2019



A handwritten signature in blue ink that reads "Ashok Somani".

Ashok Somani
Director

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
 • Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
 • Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
 Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 31ST MARCH, 2019 (Rupees in Thousands)

Sr. No.	PARTICULARS	As at 31.03.2019 Audited	As at 31.03.2018 Audited
1	ASSETS		
	Non-Current Assets		
	(A) Property, Plant and Equipement	30	21
	(B) Financial Assets		
	(i) Investment	369	187
	(ii) Long	18,417	16,884
	<i>Total Non-current Assets</i>	18,816	17,092
	Current Assets		
	(i) Cash & Cash Equivalents	4,662	76,637
	(ii) Loans	80,732	8,835
	<i>Total Current Assets</i>	85,394	85,472
	TOTAL ASSETS	104,210	102,564
2	EQUITY AND LIABILITIES		
	EQUITY		
	(a) Equity Share Capital	15,000	15,000
	(b) Other Equity	88,296	86,232
	<i>Total Equity</i>	103,296	101,232
	Liabilities		
	Non- Current Liabilities	-	-
	Current Liabilities		
	(i) Borrowings	-	-
	(ii) Other Current Liabilities	1,197	1,197
	(iii) Provisions	(283)	135
	<i>Total Current Liabilities</i>	914	1,332
	TOTAL EQUITY AND LIABILITIES	104,210	102,564

By Order of the Board
 For Chemo - Pharma Laboratories Limited


 ASHOK SOMANI
 DIRECTOR



Place : Mumbai
 Date : 27th May, 2019

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDLONE NET PROFIT FOR THE QUARTER & YEAR ENDED 31ST MARCH, 2019

(Rs. In Thousand)

PARTICULARS	STANDLONE	
	AUDITED QUARTER ENDED 31.03.2019	AUDITED YEAR ENDED 31.03.2019
Reconciliation of Profit After Tax as reported earlier:		
Net Profit / (Loss) for the Period (as per AS)	2,426	2,063
Benefit / (Charge):	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
Net Profit / (Loss) for the Period (as per AS)	2,426	2,063

Mumbai, 27th May, 2019



For Chemo Pharma Laboratories Ltd.

A handwritten signature in blue ink that reads 'Ashok Somani'.

Ashok Somani
Director